Kumamoto University Study Finds Lenacapavir Creates Non-Infectious HIV Particles

Researchers at Kumamoto University have found that the HIV drug lenacapavir binds to the viral precursor protein Gag, disrupting normal assembly and forcing the formation of giant, non-infectious particles larger than 200 nanometers in diameter, according to a study published in the Proceedings of the National Academy of Sciences.

The work, led by lecturer Kazuaki Monde of Kumamoto University and Professor Yasumasa Iwatani of Hamamatsu University School of Medicine, involved a collaboration with the University of Miyazaki, the National Hospital Organization Nagoya Medical Center, and Tokyo University of Technology. The findings were published on September 3.

Lenacapavir is a long-acting capsid inhibitor used to prevent and treat HIV infection. It is known to block early steps in the virus’s replication, such as reverse transcription and nuclear import, by disrupting mature capsid core formation. However, its effects on the late stages of the viral life cycle — when new particles assemble and bud from infected cells — have been less clear.

Using mass photometry and transmission electron microscopy, the team identified heterogeneous, virus-like particles induced by lenacapavir that measured more than 200 nanometers across, considerably larger than typical HIV particles of 100–130 nanometers. These abnormal particles contained both Gag and Env proteins and retained the ability to fuse with and enter target cells, but they could not establish productive infection due to post-entry defects.

“An important and unexpected finding of our study is that lenacapavir can bind to both precursor Gag and mature Gag, despite differences in their structures and assembly states,” Monde said.

The study also resolved a discrepancy in earlier data: p24 ELISA tests had suggested lenacapavir strongly inhibited viral release, but more sensitive assays showed suppression required higher drug concentrations. The researchers attributed this to lenacapavir reducing p24 solubility, which artificially inflated the apparent inhibition. They also observed excessive intracellular Gag processing by the viral protease in the drug’s presence, which contributed to impaired viral release.

The authors write that lenacapavir binding to immature Gag promotes aberrant particle formation, offering insights that could guide the development of next-generation therapeutics targeting late-stage assembly.

Photo of author

Health Desk

Health Desk at Archyde.

Huawei Launches OSTA O1 Pro With 16:9.5 Screen and 7,000mAh Battery